Anemia, Chronic Kidney Disease-Mineral and Bone Disorder, Chronic Kidney Diseases, Hyperglycemia, Hyperlipidemias, Hypertension, Malnutrition
Conditions
Brief summary
Objective: To establish a study cohort and follow up of patients with CKD in our hospital, and evaluate the status of integrated CKD diagnosis and treatment according to guidelines in the real world, as well as the clinical prognosis of patients with different stratification. Methods: By establishing a cohort of 1000 patients with CKD and conducting long-term follow-up, integrated diagnosis and treatment for CKD was performed, namely: Regular monitoring, control of blood pressure, blood glucose, blood lipid, correction of anemia, minerals - bone metabolic abnormalities, malnutrition, acid and alkali, and electrolyte disorder, diet and exercise, such as the guidance of integrated management, non intrusive, observational studies, prospective cohort were analyzed retrospectively, describe the implementation of the integration of diagnosis and treatment, chronic kidney disease (CKD) Stratified analysis and risk factor analysis were performed for cardiovascular disease and other main endpoint events, so as to objectively reflect the status of integrated treatment of CKD and provide data support for continuous quality improvement of CKD diagnosis and treatment and improvement of clinical prognosis of patients.
Interventions
OTHERIntegrated diagnosis and treatment for CKD
This is an observational study. Investor will not intervene the clinical practice of doctors. In the real world, there would be many factors affect the proceeding of the guidelines contents. There will be integrated diagnosis and treatment during follow-up.
Sponsors
Capital Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* ≥18 years old; * Voluntarily signed informed consent; * Patients who are estimated to develop CKD.
Exclusion criteria
* Age \< 18 or ≥100 years; * Unable to comply with the procedures stipulated in this study; * Estimated follow-up time ≤6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of cardiovascular cerebrovascular adverse events | Six months or more | Acute myocardial infarction, heart failure, shock, cardiac arrest, stroke, and lower limb arterial occlusion occurred during follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of all-cause mortality | Six months or more | Deaths from all causes during follow-up |
Countries
China
Outcome results
None listed